Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 949 of 6351
-
Tight glucose control may preserve insulin-making cells in type 2 diabetes
Disease control OngoingDiabetes is a disorder of high blood glucose, that tends to get worse; over time, patients need more and more drugs. This pattern is caused by overwork of the body's insulin-producing β-cells, because patients' glucose levels are typically above normal; if the investigators kept …
Sponsor: Foundation for Atlanta Veterans Education and Research, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Peer support may curb HIV stigma and stress in vietnamese gay men
Disease control CompletedParticipants are Vietnamese national. Over the course of the study activities, approximately 184 self-identified Vietnamese national gay and bisexual men ages 18 and above living in HCMC, Viet Nam, as well as 10 key informants (about 5 females) ages 18 and above will participate …
Sponsor: Florida State University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New antibody drug shows promise for kidney disease
Disease control CompletedRandomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
Phase 2 • Sponsor: HI-Bio, A Biogen Company • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could a two-drug cocktail reverse liver scarring in NASH patients?
Disease control CompletedThis study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH). NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, whi…
Phase 2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Treadmill training may slow Parkinson's motor decline
Disease control OngoingThis study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370…
Sponsor: Northwestern University • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New Self-Amplifying RNA vaccines show promise in early COVID-19 trial
Vaccine CompletedThis is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults previously vaccinated and not previously vaccinated ag…
Phase 1/2 • Sponsor: Arcturus Therapeutics, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 07:54 UTC
-
A safety net after jail: can checkups keep opioid treatment on track?
Disease control CompletedThe experiment will be conducted in collaboration with 6 jails representing discrete geographic counties in Illinois and the opioid treatment providers (OTP) that serve them. It will compare a re-entry as usual control group with two experimental groups in terms of their impact o…
Phase 3 • Sponsor: Chestnut Health Systems • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New rabies vaccine schedule tested in 2,000 volunteers
Vaccine CompletedTo evaluate the immunogenicity and safety of different post-exposure prophylaxis (PEP) schedules of Sinovac rabies vaccine, in comparison with a marked rabies vaccinein china, in subjects aged 10-60 years old.
Phase 3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Jun 27, 2026 08:12 UTC
-
New drug hopes to restore arm movement after spinal injury
Disease control CompletedThe purpose of this study is to compare the efficacy and safety of intravenous (IV) infusions of MT-3921 to placebo in subjects with acute traumatic cervical spinal cord injury. Subjects meeting eligibility criteria will enter the 6-month double-blind period. Subjects will be ra…
Phase 2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New combo therapy shows promise for tough head and neck cancers
Disease control CompletedEvaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st line metastatic or recurrent HNSCC with programmed death-ligand 1 (PD-L1) positive (combined positive score \[CPS\] ≥1) tumors, and determine the efficacy an…
Phase 2 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Zapping the brain to reset mood and metabolism?
Disease control OngoingDepression and metabolic disorder (MetD) are two of the most common and debilitating disorders worldwide, occurring with significant rates of comorbidity. This is a major clinical challenge as the outcomes of both conditions are worsened. Studies have uncovered that depression an…
Sponsor: National Cheng-Kung University Hospital • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New hope for kids with tough neuroblastoma: drug combo aims to shrink tumors
Disease control CompletedThe survival rate of recurrent and refractory neuroblastoma is low and the prognosis is poor. Apatinib mesylate is a highly selective small-molecule vasoendothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor. Apatinib mesylate has been shown to be safe and effec…
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a tailored drug cocktail beat lung cancer recurrence?
Disease control Recruiting nowThe purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy
Phase 3 • Sponsor: Maximilian Diehn • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy aims to slow deadly pancreatic cancer
Disease control OngoingPatients with advanced pancreas adenocarcinoma will be randomized on a 6:1 basis to receive standard of care chemotherapy followed by adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant FAK inhibitor defactinib (experimental arm) or standard of care chemot…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Needle-Free DNA vaccines aim to stop deadly Rodent-Borne viruses
Vaccine CompletedA randomized 4 cohort study that is comparing the data collected during the earlier phase study and to determine if immunogenicity can be retained with a 1 mg dose of Hantaan DNA vaccine. The study is intended to substantiate the Phase 1 results with the 2 mg dose and to also det…
Phase 2 • Sponsor: U.S. Army Medical Research and Development Command • Aim: Vaccine
Last updated Jun 27, 2026 12:35 UTC
-
Immunotherapy drug sintilimab takes on rare blood vessel cancer
Disease control Stopped earlyThis phase II trial evaluates the effect of sintilimab in treating patients with angiosarcoma that has spread to nearby tissue or lymph nodes (locally advanced), has spread to other places in the body (metastatic), or has come back (recurrent). Immunotherapy with monoclonal antib…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for kids with deadly brain cancer? drug ONC206 enters human trials
Disease control Recruiting nowThis phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary malignant CNS tumors. ONC206 is a recent…
Phase 1 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for brain lymphoma: acalabrutinib trial underway
Disease control OngoingThis research study is a Phase 1/2 clinical trial testing the safety, tolerance and efficacy of the drug Acalabrutinib for people with recurrent or refractory central nervous system lymphoma (CNSL).
Phase 1/2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Healthy meals as medicine: new study tests food support for diabetes
Disease control CompletedThis is a pragmatic randomized controlled trial (RCT) of Changing Health through Food Support for Diabetes (CHEFS-DM). This pragmatic RCT will leverage Project Open Hand's (POH) real-world programs to test the impact of a six month medically tailored food support and nutrition in…
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug duo offers hope for advanced stomach cancer patients
Disease control Recruiting nowThis is a multicentre, Phase Ib/II Clinical Study of AK109 and AK104 With or Without Chemotherapy in Second-line Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma .
Phase 1/2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC